Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000103066
Ethics application status
Approved
Date submitted
27/01/2010
Date registered
2/02/2010
Date last updated
2/02/2010
Type of registration
Prospectively registered
Titles & IDs
Public title
Study for the assessment of clinical non-inferiority and tolerability of different conjugated estrogen vaginal cream ESTROGENON (Sanval Comercio e Industria Ltda) versus PREMARIN (Wyeth Industria Farmaceutica Ltda) in women post menopause.
Query!
Scientific title
Study for the assessment of clinical non-inferiority and tolerability of different conjugated estrogen vaginal cream ESTROGENON (Sanval Comercio e Industria Ltda) versus PREMARIN (Wyeth Industria Farmaceutica Ltda) in women post menopause.
Query!
Secondary ID [1]
1352
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1113-4033
Query!
Trial acronym
CEBIO_11_2008
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Study with the purpose of check clinical non-inferiority and tolerance of two vaginal cream based on the conjugated estrogen manufactured by different manufacturers.
256600
0
Query!
Women in post menopause with indications for estrogen replacement therapy.
256719
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
256765
256765
0
0
Query!
Menstruation and menopause
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Estrogenon (conjugated estrogens), vaginal cream 0,625mg/g manufactured by Sanval Comercio e Industria Ltda,administered once a each two days for a total of 90 days, applied with cream disposable applicator, in comparasion to Premarin(Estrogen conjugated) 0,625 mg/g manufactured by Wyeth Industria Farmaceutica Ltda, taken once the each two days for a total of 90 days, administrated by cream disposable applicator.
Query!
Intervention code [1]
255859
0
Not applicable
Query!
Comparator / control treatment
Comparison of action of two differents vaginal cream of conjugated estrogens 0625mg/g, taken once the each two days, during 90 days on a clinical setting and administrated by cream disposable applicator.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
257752
0
Endometrium thickness - test used: transvaginal ultrasound exam
Query!
Assessment method [1]
257752
0
Query!
Timepoint [1]
257752
0
90 days following randomization
Query!
Secondary outcome [1]
263126
0
Alterations in clinical examination (gynecological) - Citology
Query!
Assessment method [1]
263126
0
Query!
Timepoint [1]
263126
0
90 days following randomization
Query!
Eligibility
Key inclusion criteria
Women in post menopause with indications for estrogen replacement therapy
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Patients with contraindications for estrogen use
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/03/2010
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
66
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
2417
0
Brazil
Query!
State/province [1]
2417
0
Query!
Funding & Sponsors
Funding source category [1]
256351
0
Commercial sector/Industry
Query!
Name [1]
256351
0
Sanval Comercio e Industria Ltda.
Query!
Address [1]
256351
0
R. Lagrange, 401 _ Bairro Socorro
Sao Paulo - Brazil - 04761-050
Query!
Country [1]
256351
0
Brazil
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanval Comercio e Industria Ltda.
Query!
Address
R. Lagrange, 401 _ Bairro Socorro
Sao Paulo - Brazil - 04802-000
Query!
Country
Brazil
Query!
Secondary sponsor category [1]
251665
0
None
Query!
Name [1]
251665
0
Query!
Address [1]
251665
0
Query!
Country [1]
251665
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
258467
0
Comite de Etica em Pesquisa do Hospital Belo Horizonte
Query!
Ethics committee address [1]
258467
0
Query!
Ethics committee country [1]
258467
0
Brazil
Query!
Date submitted for ethics approval [1]
258467
0
Query!
Approval date [1]
258467
0
09/03/2009
Query!
Ethics approval number [1]
258467
0
Query!
Summary
Brief summary
Patients at post-menopause phase, after signing Free and Informed Consent Term, shall pass through medical consultation and laboratorial exams (clinical analysis) including plasmatic dosing of Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), Glutamate Oxaloacetate Transaminase (GOT) and glutamic-pyruvic transaminase (GPT), calcium and Total Estrogen (Estradiol) and Free Estrogen (Free Estriol), Glucose and total Cholesterol. A mammography will be performed in order to exclude patients with counter indication for the drug use. Patients shall be sent to undergo transvaginal ultrasound exam in order to assess their endometrium thickness. During medical consultation, vaginal walls as well as the cervix will be scraped for functional cytological and oncologic exam, using Papanicolaou test method. The procedures, in total or in part, shall be repeated at the following visits, within three months follow-up time period.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
30725
0
Query!
Address
30725
0
Query!
Country
30725
0
Query!
Phone
30725
0
Query!
Fax
30725
0
Query!
Email
30725
0
Query!
Contact person for public queries
Name
13972
0
Jose Aurelio Quintao Sarmento
Query!
Address
13972
0
Av. Nicolau Alayon 441 - Interlagos - Sao Paulo - Sao Paulo -04802-000
Query!
Country
13972
0
Brazil
Query!
Phone
13972
0
+551156604001
Query!
Fax
13972
0
+551156668664
Query!
Email
13972
0
[email protected]
Query!
Contact person for scientific queries
Name
4900
0
Dr. Marco Tulio Baccarini Pires PhD
Query!
Address
4900
0
Av. Contorno 2646 - 6º andar - Belo Horizonte - Minas Gerais - 30110-014
Query!
Country
4900
0
Brazil
Query!
Phone
4900
0
+553132413458
Query!
Fax
4900
0
+553132413458
Query!
Email
4900
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF